Abstract
Highly active antiretroviral therapy (HAART) has changed the natural course of HIV infection. However, the toxicities associated with long-term use of nucleoside reverse transcriptase inhibitors (NRTIs) have led to the assessment of dual-therapy approaches with less toxicity. Atazanavir and dolutegravir have antiviral potency, tolerability and favourable metabolic profile. In suppressed HIV-infected patients, with NRTIs-related toxicity effects, the association of atazanavir and dolutegravir, favoured by their positive pharmacokinetics interaction, could be used as ‘maintenance’ antiretroviral therapy. We report a case report about one HIV-infected patient, on HAART and with a persistent suppression of HIV RNA, switched to dolutegravir 50 mg three times weekly plus atazanavir 400 mg once daily, as ‘maintenance antiretroviral therapy’, with persistence of viral suppression.
Original language | English |
---|---|
Pages (from-to) | 726-728 |
Number of pages | 3 |
Journal | International Journal of STD and AIDS |
Volume | 28 |
Issue number | 7 |
DOIs | |
Publication status | Published - 2017 |
Keywords
- Atazanavir
- dolutegravir
- maintenance antiretroviral therapy
- pharmacokinetics
ASJC Scopus subject areas
- Dermatology
- Public Health, Environmental and Occupational Health
- Pharmacology (medical)
- Infectious Diseases